𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12

✍ Scribed by S. Homma; T. Kikuchi; N. Ishiji; K. Ochiai; H. Takeyama; H. Saotome; Y. Sagawa; E. Hara; D. Kufe; J. L. Ryan; T. Ohno; G. Toda

Book ID
108711217
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
111 KB
Volume
35
Category
Article
ISSN
0014-2972

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Exploiting dendritic cells for cancer im
Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells
✍ Karine Breckpot; Carlo Heirman; Bart Neyns; Kris Thielemans πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 579 KB

## Abstract Dendritic cells (DCs) are pivotal regulators of immune reactivity and immune tolerance. The observation that DCs can recruit naive T cells has invigorated cancer immunology and led to the proposal of DCs as the basis for vaccines designed for the treatment of cancer. Designing effective

Th1 cells induce and Th2 inhibit antigen
Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells
✍ Francesco Ria; Giuseppe Penna; Luciano Adorini πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 301 KB πŸ‘ 1 views

Dendritic cells are the most relevant antigen-presenting cells (APC) for presentation of antigens administered in adjuvant to CD4 + T cells. Upon interaction with antigen-specific T cells, dendritic cells (DC) expressing appropriate peptide-MHC class II complexes secrete IL-12, a cytokine that drive